Click image to enlarge
This kit provides assay-specific components for the quantitative determination of both natural and recombinant mouse monocyte chemoatatic protein-1 (MCP-1 or CCL2) in serum and plasma.
-
-
Specifications
-
-
Documentation
-
References
Application(s)
|
|
Cytokines & Chemokines
,
Immunology/Inflammation
|
|
Analyte(s)
|
|
MCP-1
|
|
Species
|
|
Mouse
|
|
Plate Type
|
|
96-well
|
|
Instrument(s)
|
|
MESO SECTOR S 600MM
,
MESO QuickPlex SQ 120MM
,
MESO SECTOR S 600
,
MESO QuickPlex SQ 120
,
SECTOR Imager 6000
,
SECTOR Imager 2400
|
|
LLOD (Sensitivity)
|
|
9.0 pg/mL
|
|
Dynamic Range
|
|
9.0-40000 pg/mL
|
|
Sample Type
|
|
Serum, Plasma
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
Storage Statement(s)
|
|
Please refer to the product insert for the storage conditions of individual kit components.
|
|
Storage Condition
|
|
Multi-Component
|
|
Product Inserts
|
|
|
Datasheets
|
|
|
Certificate of analysis
|
|
|
SDS
|
|
|
Title
|
Journal
|
Year
|
|
Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection
|
|
|
|
Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses
|
|
|
|
Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial
|
|
|
|
CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer’s disease
|
|
|
|
Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor-modified T Cell Therapy.
|
|
|
|
View All
|
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters